Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

Active:	Yes
Cancer Type:	Breast Cancer Colon/Rectal Cancer Liver Cancer / Hepatoblastoma Lung Cancer Melanoma Ovarian Cancer Unknown Primary	NCT ID:	NCT05118841
Trial Phases:	Phase I	Protocol IDs:	ZX-4081 (primary) NCI-2022-02249
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Nanjing Zenshine Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT05118841

Summary

A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion
study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary
antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles
in patients with Advanced Solid Tumors.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.